

HOST RESPONSE TO MYCOBACTERIUM TUBERCULOSIS

Zahra Toossi and Jerrold J Ellner

Division of Infectious Diseases, Biomedical Research Building, 10th Floor West Administration, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OHIO 44106-4984

Received 6/11/98 Accepted 7/14/98

TABLE OF CONTENTS

1. Abstract
2. Introduction
3. Pathogenesis of *M. tuberculosis* infection
 - 3.1. Infection with *M. Tuberculosis*
 - 3.2. Induction of cytokines by *M. Tuberculosis*
 - 3.3 . T-cell responses during *M. tuberculosis* infection
4. Cytokine circuits during active tuberculosis
 - 4.1. the role of monocytes in immunosuppression of tuberculosis
 - 4.2. Cytokine profile of tuberculous granulomas
5. *M. Tuberculosis* infection during HIV disease
6. References

1. ABSTRACT

Critical to the complete expression of the virulence of *M. tuberculosis* and thereby its pathogenesis in human infection, is the ability of this pathogen to interact with the host in a specific manner. To date, cytokine circuits during tuberculosis and *M. tuberculosis* infection have been studied most intensely. With this regard, both the whole *M. tuberculosis* and its protein and non-protein moieties appear to be influential on the *in situ* cytokine profile, and consequently, to the final outcome of infection. The interplay and final balance of macrophage activating and immuno-enhancing cytokines versus macrophage deactivating and immunosuppressive cytokines most likely determines the final expression of *M. tuberculosis* infection. Further, cytokine circuits also underlie the immunopathology of tuberculosis. Modulation of the *in vivo* cytokine milieu may allow the development of more effective vaccines to prevent *M. tuberculosis* infection, and adjunctive immunotherapy to improve treatment of tuberculosis.

2. INTRODUCTION

Infection with *Mycobacterium tuberculosis* continues to be the most common recognized infectious disease worldwide contributing to significant morbidity and mortality (1). The interaction of the host with *M. tuberculosis* is likely to be conducive to expression of the virulence of this pathogen. In fact, the very nature of the complex interaction between the host and the organism may underlie the salient features of *M. tuberculosis* infection namely, the persistence of infection within host tissues, and the development of disease. The immune response to *M. tuberculosis* can be characterized to be both salutary to the survival of the host, contributing to control of mycobacterial replication, and damaging to the host, contributing to promotion of tuberculosis. Recent research has allowed a better understanding of the survival of the pathogen after initiation of *M. tuberculosis* infection, and the establishment

of immunopathologic circuits during tuberculosis. This knowledge may pave the way for development of both better vaccines to prevent infection with *M. tuberculosis*, and immunomodulatory approaches to aid in treatment of tuberculosis.

3. PATHOGENESIS OF *M. TUBERCULOSIS* INFECTION

In humans, infection with *M. tuberculosis* is associated with a wide spectrum of outcomes ranging from containment of infection and development of protective immunity, to development of tuberculosis as a consequence of rapid initial mycobacterial replication or reactivation of latent infection after a period of mycobacterial dormancy. The unique ability of *M. tuberculosis* to be associated with a pathogenesis allowing such diverse modes of outcome is dependent on *M. tuberculosis* virulence, which in turn is comprised of and combines the following three different components. The ability of *M. tuberculosis* to survive and replicate within host mononuclear phagocytes; the specific property of *M. tuberculosis* dormancy which allows the organism to survive for prolonged periods of time within the tissues of the host; and the intense interaction of *M. tuberculosis* with the host which contributes both to pathogenesis and protective immunity.

3.1. Infection with *M. tuberculosis*

In an *M. tuberculosis*-naive individual, subsequent to an aerosol infection with a few (up to 5) bacilli (2), a primary focus of infection is established which is initially mainly featured by the intracellular multiplication of the organism within the host's most proficient phagocytes, the alveolar macrophages (3). In fact it appears that *M. tuberculosis* has adapted to employ any of several cellular molecules abundantly present on the surface of macrophages, such as the complement receptors (CR) (CR3 and CR4) (4), fibronectin receptors (5), and mannose

Human immune response to *M. tuberculosis*

receptors (6), to gain access to the intracellular space of these professional "killer" cells. Through particular modes of intracellular trafficking and a combination of events which may include alkalization of the phagosome (7), prevention of phagosome-lysosome fusion (8), and escape from the phagosome (9), *M. tuberculosis* evades powerful intracellular killing mechanisms. Despite induction of several potent macrophage activating molecules such as tumor necrosis factor (TNF α) (10) and interleukin-1 (IL-1) (11) by *M. tuberculosis*, intracellular replication ensues. The biologic basis for the rapid intracellular replication of *M. tuberculosis* is not fully understood, however, most likely is multifactorial. Potent macrophage deactivating molecules such as transforming growth factor beta (TGF β) (12) and IL-10 (13) are induced by *M. tuberculosis*, which counteract all known macrophage activating cytokines (TNF α and IFN γ), and microbicidal molecules (reactive oxygen and nitrogen intermediaries) (14, 15). In addition, *M. tuberculosis* is well-equipped to scavenge these potent microbicidal molecules (reactive oxygen and nitrogen intermediaries) by moieties such as mycobacterial sulfatides (16) and cell wall lipoarabinomannan (17). Further, the organism's ability to alter intracellular iron concentrations, as by mycobactins (18), may allow modulation of the production of macrophage activating cytokines (19).

Soon after establishment of a focus of *M. tuberculosis* infection, with the recruitment of blood mononuclear cells, the process of *M. tuberculosis* "sensitization" of CD4 and CD8 lymphocytes is initiated. However, due to yet to be defined reasons, protective immunity requires up to 3 weeks to become adequately vigorous to contain *M. tuberculosis* growth. Meanwhile, uncontrolled intracellular replication continues which eventually may culminate in the rupture of infected phagocytes and spread of infection to other cells. Importantly, phagocyte rupture allows the initiation of both extracellular growth, and tissue damage culminating in caseation necrosis. As *M. tuberculosis* growth expands, lymphohematogenous spread allows the seeding of both pulmonary (upper lobes of the lung) and extrapulmonary sites. Finally, with the development of specific host cell-mediated immune response, mycobacterial replication is controlled and most infected individuals develop a robust life-long immunity to *M. tuberculosis*. Protective immunity involves the host's capacity to produce T-cell cytokines, that expand *M. tuberculosis* antigen reactive T-cells (IL-2) and induce macrophage activation (IFN γ), and ultimately to develop microbicidal granulomas. With this regard, the production and activity of cytokines that are crucial to the development of Th1 responses, such as by macrophage IL-12 (20), are critical to the final containment of infection. However, regardless of the development of systemic protective immunity, about 5-10% of *M. tuberculosis*-infected subjects retain the capacity to reactivate mycobacterial growth and development of tuberculosis after a short (1-2 years) or a prolonged (life-time) period of latency. The ability of *M. tuberculosis* to persist in a dormant state within host tissues is not well understood, however, most probably relates to the capacity of the pathogen to switch its metabolism from a rapid aerobic growth to a slow anaerobic growth (21). Whether the

structure of the initial granulomatous response and/or the nature of cytokines induced by *M. tuberculosis* are important in the initiation or termination of dormancy is not known. However, conditions that weaken cell-mediated immunity increase the chance of terminating the latent state of infection and development of tuberculosis (22).

The factors that are important in the maintenance of protective immunity against *M. tuberculosis* infection after primary infection (i.e immunologic surveillance) are not known. In experimental animals live but not dead organisms induce protective immunity (23), and two separate T-cell subsets confer protective immunity and delayed type hypersensitivity (24). It is possible that the sustenance of successful immunological surveillance after *M. tuberculosis* infection is contingent on a dynamic interaction *in situ* (granuloma) which is permissive to the continuous sensitization of *M. tuberculosis*-reactive T-cells, which may in turn be dependent on the low grade replication of a few remaining bacilli, periodically. Under this scenario, the co-occurrence of the breakdown of the immune system by co-conditions (such as HIV infection) with the low grade periodic mycobacterial replication within "healed" *M. tuberculosis*-infected foci, is likely to be conducive to initiation of the process of reactivation and exponential growth of *M. tuberculosis*. Whereas the actual events around reactivation are poorly understood, cytokines induced by the organism or its products may be instrumental in this process. With this regard again the capacity of *M. tuberculosis* to induce cytokines that are suppressive to T-cell function and deactivate macrophages and damage the tissues is noteworthy.

3.2. Induction of cytokines by *M. tuberculosis*

M. tuberculosis and its protein and non-protein antigens are strong stimuli for induction of cytokines in human mononuclear phagocytes which most likely affect the outcome of infection at any stage of *M. tuberculosis* infection. Early studies indicated that purified protein derivative (PPD) of *M. tuberculosis* induces the pro-inflammatory cytokines, IL-1 (11) and TNF α (10). On the other hand, *M. tuberculosis*, but not its PPD, was strong in induction of IL-12 in monocytes (25). However, *M. tuberculosis* (12), its PPD (26), and its cell wall lipoarabinomannan (LAM) (27), which constitutes 0.5% of mycobacterial weight (28), were potent inducers of TGF β . Further, the effect of LAM on induction of TGF β appeared to be dominant over induction of the pro-inflammatory cytokines (TNF α , IL-1 beta, and IL-6) and IL-10 (27). Importantly, one of the three moieties of a major secretory component of actively replicating mycobacteria (antigen 85 complex), namely 30 kD antigen (85B), strongly induces TNF α (29). Interestingly, 30 kD antigen is a fibronectin binding protein (30), and its interaction with fibronectin enhances the production of TNF α (29). More recently, 30 kD antigen has been shown to induce TGF β (31) and IL-10 (32). Of note, TGF β up-regulates its own production (33), thereby allowing a mechanism for predominance over other cytokines *in situ*. Thus, mechanisms for induction and amplification of cytokine circuits appear to be inherent to *M. tuberculosis*, its components, and its state of metabolism.

Human immune response to *M. tuberculosis*

Whereas it may be argued that the mononuclear phagocyte cytokine-inducing capacity of *M. tuberculosis* is similar to certain "physiologic" stimuli such as bacterial LPS, it certainly is not a property shared by all bacterial products. For example, early studies showed that tetanus toxoid was an extremely poor stimulus for induction of IL-1 beta as compared to mycobacterial PPD (11). Furthermore, the persistence of *M. tuberculosis* infection within host tissues allows a dominant role of mononuclear cell phagocyte cytokine profile *in situ* that may not be true in the case of infection with other bacterial pathogens.

However, at any stage of *M. tuberculosis* infection, within granulomas, the cumulative effect of *M. tuberculosis* and its moieties on mononuclear cell responses and, in particular, the cytokine profile determines the success of the host in containment of mycobacterial growth. In this regard, the *in situ* balance of macrophage activating and deactivating cytokines is critical. To date, TNF α has been shown to be modest in its anti-*M. tuberculosis* activity in human mononuclear cell *in vitro* systems (12, 34). In mice, abrogation of TNF α was associated with loss of microbicidal granulomas (35). Further, *M. tuberculosis* infection of human alveolar macrophages as compared to autologous blood monocytes, lead to significantly higher induction of TNF α (3), and production of nitric oxide (NO) (36), which correlated with the superiority of the former cell type to contain *M. tuberculosis*. A role for NO in human mycobacterial infections has been suggested, although it has not been consistently shown (37). On the other hand the ability of alveolar macrophages to produce TGF β in response to stimulation by lipopolysaccharide (LPS) was limited (38). Importantly, the potency of T-cell IFN γ as a predominant macrophage activating cytokine may be at least partly through upregulation of production of TNF α (39). Both TNF α and IFN γ induce microbicidal pathways (production of reactive oxygen and nitrogen intermediaries) in phagocytes (40). On the other hand, it appears that the main cytokines responsible for macrophage deactivation within maturing granulomas are TGF β (41) and possibly IL-10. However, the basis for macrophage deactivation by TGF β and IL-10 appears to be both directly, through inhibition of the generation of microbicidal molecules, and indirectly by counteraction to the effects of the macrophage activating cytokines (IFN γ and TNF α). Abrogation of TGF β increased (12, 42), and recombinant TGF β decreased (12) the ability of human monocytes to contain the intracellular growth of *M. tuberculosis*. Recently, it has also been suggested that the differential gradient of IFN γ activity across granulomas may be important in the fate of *M. tuberculosis in situ* (Orme unpublished). It is possible that other macrophage deactivating cytokines, such as IL-1 receptor antagonist (IL-1Ra) and IL-4, play a role in early *M. tuberculosis* granulomas. Recent data suggest that IL-1Ra is induced by *M. tuberculosis* in monocytes (Wilkinson, unpublished), and that both IL-4 (43) and TGF β (44) enhance the production of IL-1Ra. Whether production and activity of IL-1Ra correlates with particular host inflammatory responses is not known.

3.3. T-cell responses during *M. tuberculosis* infection

Evidence for the role of T-cells, in particular CD4 cells, in protective immunity against *M. tuberculosis* was established initially in experimental models of tuberculosis (24). In humans, the strongest evidence for a predominant role of CD4 cells in protective immunity is evidenced by the significant susceptibility of HIV infected populations to development of active tuberculosis (45). Further, in HIV-infected patients with tuberculosis, mycobacterial load increases as CD4 depletion becomes more prominent (46). Also, tuberculous pleuritis, which is both a paucibacillary *M. tuberculosis* infection and self-resolving, is associated with expansion of CD4 cells and abundance of IFN γ (47) locally. However, the pathogenesis of tuberculous pleuritis likely reflects a state of "hypersensitivity" of the host to *M. tuberculosis* and its products, rather than true *M. tuberculosis* infection.

The mechanisms by which CD4 cells contribute to immunosurveillance against *M. tuberculosis* include the induction of Th1 cytokines, IL-2 and IFN γ , and contact between CD4 cells and mononuclear phagocytes (48). The importance of IFN γ in protective immunity to tuberculosis derives from two separate lines of evidence. Mice with a disrupted gene for IFN γ are extremely susceptible to *M. tuberculosis* infection (49, 50). Humans who are homozygous for a mutation in IFN γ R are extremely sensitive to fatal mycobacterial infection (51). On the other hand, cytolytic activity of *M. tuberculosis* reactive CD4 cells towards *M. tuberculosis* infected target cells has been demonstrated *in vitro* (52). This mechanism may particularly contribute to apoptotic cell death of *M. tuberculosis*-infected cells at sites of active infection (53), which recently has been shown to be important in containment of intracellular mycobacterial replication (54). However, secondary to the fact that human T-cell responses to *M. tuberculosis* antigens are heterogeneous, it has been practically impossible to decipher particular *M. tuberculosis* antigens that confer protective immunity (55).

Despite a well-demonstrated role of CD8 cells in protective immunity against *M. tuberculosis* in mice (56), the role of this cell type in human infection remains unclear. However, when sensitive assays were employed, MHC class I-restricted CD8 responses to early secreted antigens, which presumably are targets of protective immunity (57) were shown in a subgroup of tuberculosis patients (58). Further, *M. tuberculosis*-specific CD8 cells appeared to function through cytolytic mechanisms (58). Similarly, whereas $\gamma\delta$ T cells have been shown to demonstrate innate reactivity to *M. tuberculosis* (59), produce IFN γ and lyse *M. tuberculosis*-infected targets (60), their role in immunosurveillance against *M. tuberculosis* remains unclear. On the other hand, both CD8 and $\gamma\delta$ T-cells types may contribute to host defense early during primary *M. tuberculosis* infection.

4. CYTOKINE CIRCUITS DURING ACTIVE TUBERCULOSIS

Up to 60% of patients with active pulmonary tuberculosis, the predominant clinical form of disease,

Human immune response to *M. tuberculosis*




Figure 1. Longitudinal analysis of cytokines induced by PPD of *M. tuberculosis* in PBMC of patients with pulmonary tuberculosis and healthy PPD skin test reactive control subjects. PBMC were isolated from patients with tuberculosis at the time of diagnosis (T0), and 3, 6, and 12 months (MO) after initiation of anti-tuberculous therapy. PBMC were cultured with and without PPD (10 mg/ml), and culture supernatants harvested. PBMC from control subjects were only assessed for cytokine production concurrent with enrollment of patients at T0. Cytokines (IFN γ , TNF α , TGF β , and IL-10) were assessed in culture supernatants. All patients were treated successfully (i.e. without treatment failure) with short course chemotherapy (6 months) (Hirsch & Ellner, unpublished data).

demonstrate suppression of their *in vitro* T-cell responses to mycobacterial antigens (61). Suppression of T-cell responses correlates with the extent of tuberculosis radiographically, and is associated with loss of cutaneous DTH response (i.e. PPD skin test), (62). The basis for low T-cell responses is not due to changes in the relative numbers of the main T-cell populations (63), and despite possible concentration and/or expansion of *M. tuberculosis*-reactive cells at sites of active infection, low responses are not due to lack of antigen-responsive T-cells in the blood (64). We have described a functional suppression of T-cell responses to mycobacterial antigens that encompasses both low Th1 cytokine production (IL-2 and IFN γ) and T-cell proliferative responses (IL-2 responses) (62, 65). The molecular basis of T-cell suppression during active tuberculosis has been identified to be predominantly TGF β (62). Levels of TGF β in plasma in fact correlate with extent of tuberculosis (62), and stimulated release of TGF β corrects to that seen in healthy subjects by 3-6 months after initiation of therapy (Hirsch unpublished). Importantly, in the latter study stimulated production of IFN γ remained significantly low until time points well after completion of chemotherapy (Figure 1). These data may imply mechanisms other than and in addition to that mediated by immunosuppressive cytokines in modulation of IFN γ response during tuberculosis.

4.1. The role of monocytes in immunosuppression of tuberculosis

Evidence for a predominant role of blood monocytes in suppression of T-cell responses during tuberculosis derives from several studies. Depletion of

adherent monocytes from peripheral blood mononuclear cells of patients with pulmonary tuberculosis enhances T-cell responses (65, 66), including the production of IL-2 (65) and IFN γ (31). On the other hand, small numbers of monocytes when added back to T-cell cultures, suppress T-cell functions (67). Further, monocytes from patients with tuberculosis spontaneously express IL-2R on their surface (68), and display an activation of nuclear factor κ B (NF κ B) (69). When cultured with exogenous IL-2, monocytes from patients remove IL-2 from supernatants (68). Also, the production of the proinflammatory cytokines, are upregulated upon *in vitro* stimulation with PPD or LPS (70, 71).

The mechanisms by which monocytes from patients with tuberculosis suppress T-cell responses are in part known. First, in spite of expression of functional IL-2 R, the blastogenic defect of PBMC is only partly corrected by exogenous IL-2 (68). On the other hand, monocytes from patients with active pulmonary tuberculosis spontaneously express TGF β (41), and produce augmented amounts of TGF β upon stimulation by PPD or 30 kD antigen of *M. tuberculosis* (62, 31). By contrast, concentrations of IL-10 in monocyte cultures of patients with tuberculosis were either similar (62), or only slightly increased (figure 1) as compared to that of control subjects. Abrogation of TGF β by neutralizing antibody or natural inhibitors of TGF β enhanced T-cell responses to PPD in PBMC of patients (62, 42).

4.2. Cytokine profile of tuberculous granulomas

Recently, Shwander et al have shown an alveolitis featured by the presence of abundant numbers of immature mononuclear phagocytes, which by cytoasting are indistinguishable from monocytes, in bronchoalveolar lavages of the tuberculosis involved lungs (as compared to the uninvolved lung) of patients with tuberculosis (72). Whereas active recruitment of blood monocytes to sites of infection underlies the latter finding, the cytokine profile of monocytes may well be reflected at sites of tuberculous granulomas. We have identified TGF β , but not TNF α , in tuberculous granulomas of patients with active untreated tuberculosis (41). In the above mentioned study (72), despite the fact that the distribution of lung CD4 and CD8 cells simulated that of the blood, there appeared to be a concentration of naive but not memory T-cells in the tuberculosis involved lungs. However, alveolar T-cells were "hyper-responsive" to *M. tuberculosis* antigens as compared to PBMC *in vitro* (Schwander, unpublished). Whether these dysregulations of mononuclear cells at sites of infection contribute to the inability of the host to contain *M. tuberculosis* or to immunopathology is not known.

4.3. Role of cytokines in immunopathology of tuberculosis

The clinical hallmark of tuberculosis include features such as fever, weight loss, and inanition. Whereas, the immunopathology of chronic *M. tuberculosis* infection is characterized by extensive tissue destruction, formation of cavities, and fibrosis. Many of the mentioned features of tuberculosis are likely cytokine-mediated, and correlate with cytokines measured systemically. TNF α is cytotoxic to epithelial cells, reduces the production of surfactant protein

Human immune response to *M. tuberculosis*

by type II alveolar cells, promotes fibroblast activity, enhances the production of fibroblast collagenases, and promotes the production of reactive oxygen intermediaries that are cytotoxic to tissues (73). Further, TNF α potentiates the cellular toxicity of *M. tuberculosis* (39). On the other hand, excessive production of TGF β is associated with extensive fibrosis and tissue damage (74). TGF β is a strong inhibitor of epithelial and endothelial cell growth (75), and it both promotes the production and deposition of collagen matrix(76), and enhances tissue degradation through induction of the production of macrophage collagenases (77). In experimental animals, systemic administration of TGF β is associated with cachexia and generalized fibrosis (78). Further, in humans undergoing chemotherapy, high plasma TGF β correlated strongly with the development of liver and lung fibrosis (79). The pathogenesis of many human fibrosing diseases has been in fact associated with TGF β (80).

4.3. Modulation of the host responses to *M. tuberculosis*

The elucidation of cytokine pathways during *M. tuberculosis* infection and during tuberculosis allows the application of immunomodulatory approaches to both vaccination against the organism, and management of tuberculosis. It is of note that certain cytokines, such as IL-12, boost immunologic responses to microbial antigens, and therefore may prove to be ultimately useful as adjuvants in the design of protective vaccines (81). On the other hand, in a study of immunization of mice against *Shistosoma mansoni*, vaccination routes that were conducive to expression of TGF β were associated with failure of development of protective immunity (82). As noted, *M. tuberculosis* and its moieties induce TGF β in mononuclear cells (12, 26, 27, 31). The above considerations need to be incorporated in the design of a new vaccine to successfully induce protective immunity against the *M. tuberculosis*.

5. *M. TUBERCULOSIS* INFECTION DURING HIV DISEASE

As noted, conditions that weaken cell-mediated immunity increase the chance of terminating *M. tuberculosis* latency subsequent to a primary infection, and increase the chance of development of tuberculosis. The fact that infection with human immunodeficiency (HIV) is the strongest risk factor for development of tuberculosis in the *M. tuberculosis* infected host, underscores the role of T-cells, and in particular CD4 cells, in immunosurveillance against *M. tuberculosis* infection. On the other hand, the fact that tuberculosis is the commonest and the earliest opportunistic infection in HIV infected subjects worldwide, in turn underscores the virulence of *M. tuberculosis* in humans.

However, during active *M. tuberculosis* infection in an HIV-infected subject, an intense interaction is initiated between the host and these pathogens which ultimately culminates in enhanced viral load (83), and augmented HIV-related mortality and morbidity (84). With regard to immunologic responses to *M. tuberculosis*, patients with dual infection display even more dramatic suppression of

IFN γ production (85), and increase in TNF α (86) and TGF β (85). Enhanced TNF α and TGF β activity during dual HIV tuberculosis may contribute to augmentation of viral replication and dissemination.

6. REFERENCES

1. Snider DE, Raviglione M, Kochi A. Global burden of tuberculosis. In "Tuberculosis pathogenesis, protection, and control" Ed: B Bloom ASM Press.Washington, DC_3-11 (1994)
2. Smith, DW, Wiegshauss EH, Navalkar R, Grover AA: Host-parasite relationships in experimental airborne tuberculosis. I. Preliminary studies in BCG-vaccinated and nonvaccinated animals. *J. Bacteriol.* 91, 718-724 (1966)
3. Hirsch CS, Ellner JJ, Russell DG, Rich EA. Complement reseptor mediated uptake and tumor necrosis a-mediated growth inhibition of *Mycobacterium tuberculosis* by human alveolar macrophages. *J Immunol* 152, 743-749 (1994)
4. Schlesinger LS, Bellinger-Kawahara CG, Payne NR, Horowitz MA: Phagocytosis of *Mycobacterium tuberculosis* is mediated by human monocyte complement receptors and complement component C3. *J Immunol* 144, 2771-2780 (1990)
5. Ratliff TL, McGarr JA, Abou-Zied C, & Brown EJ: Attachment of mycobacteria to fibronectin-coated surfaces. *J Gen Microbiol* 134, 1307-1313 (1988)
6. Schlesinger LS: Macrophage phagocytosis of virulent but not attenuated strains of *Mycobacterium tuberculosis* is mediated by mannose receptors in addition to complement receptors. *J Immunol* 150, 2920-2930 (1993)
7. Gordon, A.H., P. D'Arcy Hart, and M.R. Young: Ammonia inhibits phagosome-lysosome fusion in macrophages. *Nature (London)* 286, 79-81 (1980)
8. Armstrong, J.A., and P. D'Arcy Hart: Phagosome-lysosome interactions in cultured macrophages infected with virulent tubercle bacilli. Reversal of the usual fusion pattern and observation on bacterial survival.*J Exp Med* 142, 1-16 (1975)
9. McDonough, K.A., Y. Kress, and B.R.Bloom: Pathogenesis of tuberculosis: interaction of *Mycobacterium tuberculosis* with macrophages . *Infect Immun* 61, 2763-2773. (1993)
10. Valone SE, Rich EA, Wallis RS, Ellner J: Expression of tumor necrosis factor alpha *in vitro* by human mononuclear phagocytes stimulated with whole *Mcobacterium bovis* BCG and mycobacterial antigens. *Infect. Immun* 56, 3313-331 (1988)
11. Wallis RS, Fujiwara H, Ellner JJ: Direct stimulation of monocyte release of interleukin 1 by mycobacterial protein antigens. *J Immunol* 136, 193-196 (1996)
12. Hirsch CS, Yoneda T, Ellner JJ, Averill LE, Toossi Z: Enhancement of intracellular growth of *M. tuberculosis* in

Human immune response to *M. tuberculosis*

human monocytes by transforming growth factor beta. *J Infect Dis* 170, 1229-1237 (1994)

13. Lin Y, Zhang H, Gong J, Barnes PF: Absence of a prominent TH2 cytokine response in human tuberculosis *Infect Immun*. 64, 1351-1356 (1996)

14. Ding A, Nathan C, Srimal S: Macrophage deactivating factor and TGF β inhibit macrophage nitrogen oxide synthesis by IFN γ . *J Immunol* 145, 940-945 (1990)

15. Bogdan C, Paik J, Vodovotz Y, Nathan C: Contrasting mechanisms for suppression of macrophage cytokine release by transforming growth factor beta and interleukin-10. *J Biol Chem* 267, 23301-6 (1992)

16. Goren MB, Brokl O, Roller HM & Das BC: Sulfatides of *Mycobacterium tuberculosis*: the structure of the principal sulfatide (SL-1) *Biochemistry* 15, 2728-2735, (1976)

17. Chan J, Fan XD, Hunter SW, Brennan PJ, Boom BR: Lipoarabinomannan, a possible virulence factor involved in persistence of *Mycobacterium tuberculosis* within macrophages. *Infect Immun* 59, 1755-1761 (1991)

18. Snow GA. Mycobactins: iron-chelating growth factors from mycobacteria. *Bacteriol Rev* 34, 99-125 (1970)

19. Silver BJ, Hamilton BD, Toossi Z: Suppression of TNF α gene expression by hemin: implications for the role of iron homeostasis in host inflammatory responses. *J Leuk Biol* 62, 547-552 (1997)

20. Wu CY, Demeure C, Kuniwa M, Gately M, Delepe G: IL-12 induces the production of IFN γ by neonatal human CD4 T cells. *J Immunol* 151, 1938-1949 (1993)

21. Wayne LG, Hayes LG: An in vitro model for sequential study of shutdown of *Mycobacterium tuberculosis* through two stages of nonreplicating persistence. *Infect Immun* 64, 2062-2069 (1996)

22. American Thoracic Society: Treatment of tuberculosis and tuberculosis infection in adults and children. *Am Rev Respir Dis* 134, 355-363, (1986)

23. Amara RR, Satchidanandam V: Differential immunogenicity of novel *Mycobacterium tuberculosis* antigens derived from live and dead bacilli. *Infect Immun* 65, 4880-4882, (1997)

24. Orme I, Collins FM: Adoptive protection of the *Mycobacterium tuberculosis*-infected lung: Dissociation between cells that passively transfer protective immunity and those that transfer delayed type hypersensitivity. *Cell Immunol* 84, 113-120 (1984)

25. Fulton SA, Johnsen JM, Wolf, S.F., Sieberth DS, Boom, WH: Interleukin-12 production by human monocytes infected with *Mycobacterium tuberculosis*: role of phagocytosis. *Infect Immun* 64, 2523 (1996)

26. Toossi Z, Young TG, Averill LE, Hamilton BD, Shiratsuchi H, Ellner JJ: Induction of transforming growth

factor beta (TGF β) by purified protein derivative (PPD) of *Mycobacterium tuberculosis*. *Infect Immun*. 63, 224-228 (1995)

27. Dahl KE, Shiratsuchi H, Hamilton BD, Ellner JJ, Toossi Z: Selective induction of TGF β in human monocytes by lipoarabinomannan of *M. tuberculosis*. *Infect Immun* 64, 399-405 (1996)

28. Hunter, S.W., Gaylord, and P.J. Brennan. Structure and antigenicity of the phosphorylated lipopolysaccharide antigens from the leprosy and tubercle bacilli. *J Biol Chem* 261, 12345-12351. (1986)

29. Aung H, Toossi Z, Wisniewski JJ, Culp LA, Phillips NB, Averill LE, Daniel TM, Ellner JJ: Induction of monocytes expression of tumor necrosis factor alpha by the 30 kDa alpha antigen of *Mycobacterium tuberculosis* and synergism with fibronectin. *J Clin Invest* 98, 1261-1268 (1996)

30. Abou-Zeid C, Ratliff TL, Wiker HG, Harboe M, Bennedsen J, Rook GAW: Characterization of fibronectin-binding antigens released by *Mycobacterium tuberculosis* and *Mycobacterium bovis* BCG. *Infect Immun* 56, 3046-3047 (1988)

31. Hirsch CS, Toossi Z, Hussain R, Ellner JJ. Suppression of T-cell responses by TGF β in tuberculosis. *J Invest Med* 43, 365A (1996)

32. Torres M, Herrera T, Villareal H & Sada E: Cytokine profiles for peripheral blood lymphocytes from patients with active pulmonary tuberculosis and healthy household contacts in response to 30 kD antigen of *Mycobacterium tuberculosis*. *Infect Immun* 66, 176-180 (1998)

33. Kim SJ, Angel P, Lafyatis R, & Roberts AB: Autoinduction of transforming growth factor beta1 is mediated by the AP-1 complex. *Mol Cell Bio* 10, 1492-5 (1990)

34. Denis M: Killing of *Mycobacterium tuberculosis* within human monocytes: activation by cytokines and calcitriol. *Clin. Exp. Immunol.* 84, 200-208 (1991)

35. Kindler V, Syepino AP, & Gran GE: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. *Cell* 56, 731-740 (1989)

36. Rich EA, Knuth CK, Hamilton BD, Toossi Z: *Mycobacterium tuberculosis*-stimulated expression of inducible nitric oxide synthase and production of nitric oxide by human alveolar macrophages. *Tubercle* In press (1997)

37. O'Brien L, Roberts B, Andrew PW: In vitro interactions of *Mycobacterium tuberculosis* and macrophages: Activation of anti-mycobacterial activity of macrophages and mechanisms of anti-mycobacterial activity. In Current Topics of Microbiology and Immunology: Tuberculosis. Ed Shinnick TM. p97-122 (1996)

38. Toossi Z, Hirsch CS, Hamilton BD, Knuth CK, Friedlander MA, Rich EA: Decreased production of

Human immune response to *M. tuberculosis*

transforming growth factor beta1 (TGF β 1) in human alveolar macrophages. *J Immunol* 156, 3461-68 (1996)

39. Rook GAW, Taverne J, Leveton C, Steele J: The role of gamma interferon, vitamin D3 metabolites, and tumor necrosis factor in the pathogenesis of tuberculosis. *Immunology* 67, 229-234 (1987)

40. Flesch IEA, Kaufmann SHE: Activation of tuberculostatic macrophage functions by gamma interferon, interleukin-4, and tumor necrosis factor. *Infect Immun* 58, 2675-2677 (1990)

41. Toossi Z, Gogate P, Shiratsuchi H, Young T, Ellner JJ: Enhanced production of transforming growth factor beta (TGF β) by blood monocytes from patients with active tuberculosis and presence of TGF β in tuberculous granulomatous lung lesions. *J. Immunol* 154, 465-473 (1995)

42. Hirsch CS, Ellner JJ, Blinkhorn R, Toossi Z: In Vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against *Mycobacterium tuberculosis* by natural inhibitors of transforming growth factor beta. *Proc Natl Acad Sciences USA* 94, 3926-3931 (1997)

43. Chizzolini C, Chicheportiche R, Burger D, Dayer J-M: Human Th1 cells preferentially induce interleukin (IL-1)-1 beta while Th2 cells induce IL-1 receptor antagonist production upon cell/cell contact with monocytes. *Eur J Immunol* 27, 171-177 (1997)

44. Turner M, Chantry D, Katsikis P, Berger A, Brennan GA, Feldman M: Induction of IL-1 receptor antagonist protein by transforming growth factor beta. *J Immunol* 121, 1635-42 (1991)

45. Barnes PF, Bloch AB, Davidson PT, Snider DE: Tuberculosis in patients with human immunodeficiency virus infection *N Engl J Med* 324, 1644-1650 (1991)

46. Lucas S, Nelson AM: Pathogenesis of tuberculosis in human immunodeficiency virus-infected people. In "Tuberculosis pathogenesis, protection, and control" Ed: B Bloom ASM Press, 503-513(1994)

47. Barnes PF, Fong F-J, Brennan PJ, Twomey PE, Mazmuder A, Modlin RL: Local Production of TNF α and IFN γ in tuberculous pleuritis. *J. Immunol* 45, 149-154 (1990)

48. Silver RF, Li Q, Boom HW, Ellner JJ: Lymphocyte-dependent inhibition of growth of virulent *Mycobacterium tuberculosis* H37Rv within human monocytes: Requirement for CD4+ T cells in purified protein derivative-positive, but not in purified protein derivative-negative subjects. *J. Immunol* 160, 2408-2417 (1998)

49. Flynn JL, Chan J, Triebold KJ, Dalton DK, Stewart TA, Bloom BR. An essential role for interferon gamma in resistance to *Mycobacterium tuberculosis*. *J Exp Med* 178:2249-2254 (1993)

50. Cooper MA, Dalton DK, Stewart TA, & Orme IM: Disseminated tuberculosis in interferon gamma gene-disrupted mice. *J Exp Med* 178: 2243-2247 (1993)

51. Newport MJ, Huxley CM, Hustons S & Levin M: A mutation in interferon-gamma receptor gene and sensitivity to mycobacterial infection. *N Engl J Med* 335, 1941-1949 (1996)

52. Lorgat F, Keraan MM, Lukey PT, Riss SR: Evidence for *in vivo* generation of cytotoxic T cells: PPD-stimulated lymphocytes from tuberculous pleural effusions demonstrate enhanced cytotoxicity with accelerated kinetics of induction. *Am Rev Respir Dis* 145, 418-423 (1992)

53. Keane J, Sablinska K, Remold HG & Kornfeld H: Infection by *Mycobacterium tuberculosis* promotes human alveolar macrophage apoptosis *Infect Immun* 65, 298-304, (1997)

54. Molloy A, Laochumroonvorapong P, Kaplan G: Apoptosis but not necrosis is coupled with killing of intracellular *Bacillus Calmette-Guerin*. *J Exp Med* 180, 1499-1510 (1994)

55. Havlir DV, Wallis RS, Boom WH & Ellner JJ: Human immune response to *Mycobacterium tuberculosis* antigens. *Infect Immun* 59, 665-670 (1991)

56. Flynn JL, Goldstein MM, Triebold KJ & Bloom BR: Major histocompatibility complex class 1-restricted T cells are required in resistance to *Mycobacterium tuberculosis* infection. *Proc Natl Acad Sci USA* 89, 12013-12017 (1992)

57. Horwitz MA, Lee B-W, Dillon O & Harth G: Protective immunity against tuberculosis induced by vaccination with major extracellular proteins of *Mycobacterium tuberculosis*. *Proc Natl Acad Sci. USA* 92, 1530-1534 (1995)

58. Lalvani A, Brookes R, Wilkinson RJ, & Hill AV: Human cytolytic and interferon gamma secreting CD8+ T lymphocytes specific for *Mycobacterium tuberculosis*. *Proc Natl Acad Sci USA* 95, 270-275 (1998)

59. Tsyuyuguchi I, Kawasumi H, Ueta C & Kishimoto S: Increase of T-cell receptor gamma-delta bearing T-cells in cord blood of newborn babies obtained by in vitro stimulation with mycobacterial cord factor. *Infect Immun* 59, 3053-3059 (1991)

60. Tsukaguchi K, Balaji KN, Boom WH: CD4+ ab T cells and gd T cells responses to *Mycobacterium tuberculosis*: similarities in Ag recognition, cytotoxic effector function, cytokine production *J Immunol* 154, 1786-1796 (1995)

61. Ellner JJ: The human response in tuberculosis. *J Infect Dis* 176, 1351-9 (1997)

62. Hirsch CS, Hussain R., Toossi Z, Ellner JJ: Cross-modulatory role for transforming growth factor beta in tuberculosis; Suppression of antigen driven interferon gamma production. *Proc Natl Acad Sci USA* 93, 3193-3198 (1996)

Human immune response to *M. tuberculosis*

63. Kleinhenz ME, Ellner JJ: Immunoregulatory adherent cells in human tuberculosis: radiation-sensitive antigen-specific suppression by monocytes. *J Infect Dis* 152, 171-76 (1987)
64. Fujiwara H, Tsuyuguchi I: Frequency of tuberculin-reactive T-lymphocytes in pleural fluid and blood from patients with tuberculous pleuritis. *Chest* 89,530-535 (1984)
65. Toossi Z, Kleinhenz ME, and Ellner JJ: Defective interleukin-2 production and responsiveness in human pulmonary tuberculosis. *J Exp Med* 163, 1162-67 (1986)
66. Ellner JJ: Suppressor adherent cells in human tuberculosis. *J. Immunol.* 121, 2573-2578 (1978)
67. Toossi Z, Edmonds KE, Tomford WJ, Ellner JJ: Suppression of PPD-induced interleukin-2 production by interaction of CD 16 lymphocytes and adherent mononuclear cells in tuberculosis. *J Infect Dis* 159, 352-356 (1989)
68. Toossi Z, Lapurga J, Ondash R, Sedor J, and Ellner JJ: Expression of functional IL-2 receptors by peripheral blood monocytes from patients with active pulmonary tuberculosis. *J Clin Invest* 85, 1777-83 (1990)
69. Toossi Z, Hamilton BD, Averill LE & Salvekar A: Regulation of nuclear factor kappa B (NF-kB) and its inhibitor, I κ B/MAD3 in monocytes during active tuberculosis and by purified derivative of *M. tuberculosis*. *J Immunol* 159, 4109-4116 (1997)
70. Ogawa T, Uchida H, Kusumoto Y, & Hamada S: Increase in tumor necrosis factor alpha and interleukin-6 secreting cells in peripheral blood mononuclear cells from subjects infected with *Mycobacterium tuberculosis*. *Infect.Immun.* 59, 3021-3025 (1991)
71. Fujiwara H, Kleinhenz ME, Wallis RS, Ellner JJ: Increased interleukin-1 production and monocyte suppressor cell activity associated with human tuberculosis. *Am Rev Respir Dis* 133, 73-77 (1986)
72. Shwander SK, Sada E, Torres M, Escobedo D, Sierra JG, Alt S, Rich EA. T lymphocytic and immature macrophage alveolitis in active pulmonary tuberculosis. *J Infect Dis* 173, 1267-72 (1996)
73. Solis-Herruzo JA, Brenner Da, Chojkier M: Tumor necrosis factor alpha inhibits collagen gene transcription and collagen synthesis in cultured human fibroblasts. *J Bio Chem* 263, 5841-45 (1988)
74. Border WA, Rusolahti ER: Transforming growth factor beta in disease: The dark side of tissue repair. *J. Clin. Invest* 90, 1-7 (1992)
75. Sporn MB, Roberts AB, Wakefield LM, Assoian RK: Transforming growth factor beta biological function and chemical structure. *Science* 233, 532-5 (1986)
76. Kasahari VM, Chen YQ, Su MW, Ramirez F, Uitto J: Tumor necrosis factor alpha and interferon gamma suppress the activation of human type I collagen gene expression by transforming growth factor beta1. *J Clin Invest* 86, 1489-94 (1990)
77. Wahl SM, Allen JB, Weeks BS: Transforming growth factor beta enhances integrin expression and type IV collagenase secretion in human monocytes. *Proc Natl Acad Sciences USA* 90, 4577-81 (1993)
78. Zugmaier G, Paik S, Wilding G: Transforming growth factor beta1 induces cachexia and systemic fibrosis without an antitumor effect in nude mice. *Cancer Res* 51, 3590-3594 (1991)
79. Anscher MS, Peters WP, Reisenbichler H & Jirtle RL: Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. *N Engl J Med* 328, 1592-96 (1993)
80. Border WA, Noble NA: Transforming growth factor beta in tissue fibrosis. *N. Engl J Med* 331, 1286-1290 (1994)
81. Romani L, Pucetti P, Bistone F: Interleukin-12 in infectious diseases. *Clin Microb Rev* 10, 611-636 (1997)
82. Williams ME, Caspar P, Oswald I, & James SL: Vaccination routes that fail to elicit protective immunity against *Schistosoma mansoni* induce TGF β , which down regulates macrophage antiparasitic activity. *J Immunol* 154, 4693-4700 (1997)
83. Fauci, A: Host factors and the pathogenesis of HIV-induced disease. *Nature* 384, 529-534 (1996)
84. Whalen CC, Horsburgh CR, Hom D & Ellner JJ: Accelerated clinical course of human immunodeficiency virus infection following active tuberculosis. *Am J Respir Crit Care Med* 151, 129-135 (1995)
85. Hirsch CS, Toossi Z, Whalen C, & Ellner JJ: Copathogenesis of tuberculosis and HIV-1 infection. Proceedings from the Thirty-second U.S. Japan cooperative medical science program tuberculosis-leprosy research conference. NIAID, NIH. July, 157-160, (1997)
86. Wallis RS, Vejeha M, Amir-Tahmasseb M & Ellner JJ: Influence of tuberculosis on human immunodeficiency virus (HIV-1): enhanced cytokine expression and elevated β 2-microglobulin in HIV-1-associated tuberculosis. *J Infect Dis* 167, 43-48 (1993)

Key Words: *M. Tuberculosis*, Tuberculosis, Cytokine, Pathogenesis, Immunity, Cell-Mediated Immune Response

Send correspondence to: Dr Zahra Toossi, Division of Infectious Diseases, Biomedical Research Building, 10th Floor West Administration, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, Ohio 44106-4984, Tel: (216)-368-4844, Fax:(216)-368-2034, E-mail: zxt2@po.cwru.edu